Precigen Reports Strong Q1 2026 Results, $21.6M PAPZIMEOS Revenue, Projects Cash Flow Break-Even by Year-End
PGEN has more than doubled off its 52-week low of $1.26.
Summary
Precigen announced strong Q1 2026 financial results with $21.6 million in PAPZIMEOS product revenue and a significantly reduced net loss, projecting cash flow break-even by year-end 2026.
Key Events · Earnings and Guidance · PGEN
-
Strong Q1 2026 Financial Performance
Reported $21.6 million in net product revenue from PAPZIMEOS in its first full quarter of commercial launch, contributing to a total revenue of $23.252 million.
-
Significant Reduction in Net Loss
Net loss dramatically decreased to $7.9 million ($0.02 per share) in Q1 2026, compared to $54.2 million ($0.18 per share) in Q1 2025.
-
Projected Cash Flow Break-Even
The company anticipates funding its operations to cash flow break-even by the end of 2026, supported by current cash and expected PAPZIMEOS sales.
-
PAPZIMEOS Commercial Momentum
The PAPZIMEOS launch shows strong traction with approximately 400 patients enrolled in the patient hub, broad payer coverage (over 90% of insured US lives), and the implementation of a permanent J-code effective April 1, 2026, streamlining reimbursement.
Analysis · PGEN · Life Sciences
Precigen reported significantly improved first-quarter 2026 financial results, driven by the successful commercial launch of PAPZIMEOS, its first FDA-approved product. The substantial reduction in net loss and the projection to reach cash flow break-even by the end of 2026 are critical for the company's financial stability and future operations, especially following a large net loss in 2025.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PGEN was trading at $4.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $1.26 to $5.47. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.